| |
| |
|
| Insider
Information: |
Goddard Glenn |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
69,213 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,652,806 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
69,213 |
|
|
| Total
Value |
$1,652,806 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -73.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agios Pharmaceuticals Inc |
AGIO |
Senior Vice President,... |
2015-09-24 |
0 |
2014-01-21 |
0 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
69,213 |
2021-08-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,628 |
69,213 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$158,053 |
D/D |
(5,365) |
40,585 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
45,950 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,484 |
42,888 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
17,831 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,720 |
14,769 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
3,062 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2022-01-01 |
4 |
S |
$112.24 |
$113,699 |
D/D |
(1,013) |
2,049 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-09-07 |
4 |
AS |
$180.12 |
$627,178 |
D/D |
(3,482) |
0 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-09-07 |
4 |
OE |
$14.58 |
$50,768 |
D/D |
3,482 |
3,482 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-31 |
4 |
AS |
$160.22 |
$3,973,456 |
D/D |
(24,800) |
0 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-31 |
4 |
OE |
$14.58 |
$469,374 |
D/D |
24,800 |
24,800 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-30 |
4 |
AS |
$153.22 |
$810,082 |
D/D |
(5,200) |
0 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-30 |
4 |
OE |
$19.27 |
$100,204 |
D/D |
5,200 |
5,200 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-05 |
4 |
AS |
$150.65 |
$3,021,056 |
D/D |
(20,000) |
0 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, Chief Financial Officer |
• – – |
2021-08-05 |
4 |
OE |
$19.27 |
$385,400 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-09-24 |
4 |
AS |
$85.97 |
$515,820 |
D/D |
(6,000) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-09-24 |
4 |
OE |
$0.00 |
$19,774 |
D/D |
10,856 |
6,000 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-09-24 |
4 |
D |
$88.89 |
$431,650 |
D/D |
(4,856) |
5,144 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-07-23 |
4 |
AS |
$120.45 |
$843,150 |
D/D |
(7,000) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-07-23 |
4 |
OE |
$23.10 |
$210,216 |
D/D |
7,000 |
7,000 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-07-17 |
4 |
AS |
$113.71 |
$1,478,230 |
D/D |
(13,000) |
0 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-07-17 |
4 |
OE |
$0.69 |
$76,603 |
D/D |
13,000 |
13,000 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-05-27 |
4 |
OE |
$23.10 |
$50,150 |
D/D |
2,171 |
2,171 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Senior Vice President, Finance |
• – – |
2015-05-27 |
4 |
AS |
$120.05 |
$260,629 |
D/D |
(2,171) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
